Loading…

The Effect of Citrus aurantium on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology

Purpose. To screen the main active components of Citrus aurantium through a network pharmacology approach, construct a component-disease target network, explore its molecular mechanism for the treatment of non-small-cell lung cancer (NSCLC), and validate it experimentally. Methods. The active ingred...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2023, Vol.2023 (1), p.6407588-6407588
Main Authors: Yao, Liangliang, Zhang, Xuan, Huang, Chaoming, Cai, Yi, Wan, Chunpeng (Craig)
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c476t-4ea760b80ce6ed7d4fe40975eddfdd95efa3628780dbd4569e9d02601ad35a733
cites cdi_FETCH-LOGICAL-c476t-4ea760b80ce6ed7d4fe40975eddfdd95efa3628780dbd4569e9d02601ad35a733
container_end_page 6407588
container_issue 1
container_start_page 6407588
container_title BioMed research international
container_volume 2023
creator Yao, Liangliang
Zhang, Xuan
Huang, Chaoming
Cai, Yi
Wan, Chunpeng (Craig)
description Purpose. To screen the main active components of Citrus aurantium through a network pharmacology approach, construct a component-disease target network, explore its molecular mechanism for the treatment of non-small-cell lung cancer (NSCLC), and validate it experimentally. Methods. The active ingredients in Citrus aurantium and the targets of Citrus aurantium and NSCLC were collected through the Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform (TCMSP), GeneCards, and OMIM databases. The protein interaction network was constructed using the STRING database, and the component-disease relationship network graph was analyzed using Cytoscape 3.9.1. The Metascape database can be used for GO and KEGG enrichment analyses. The Kaplan-Meier plotter was applied for overall survival analysis of key targets of Citrus aurantium in the treatment of NSCLC. Real-time PCR (RT-PCR) and Western blotting were used to determine the mRNA and protein levels of key targets of Citrus aurantium for the treatment of NSCLC. Results. Five active ingredients of Citrus aurantium were screened, and 54 potential targets for the treatment of NSCLC were found, of which the key ingredient was nobiletin and the key targets are TP53, CXCL8, ESR1, PPAR-α, and MMP9. GO and KEGG enrichment analyses indicated that the mechanism of nobiletin in treating NSCLC may be related to the regulation of cancer signaling pathway, phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) signaling pathway, lipid and atherosclerosis signaling pathway, and neurodegenerative signaling pathway. The experimental results showed that nobiletin could inhibit the proliferation of NSCLC cells and upregulate the levels of P53 and PPAR-α and suppress the expression of MMP9 (P
doi_str_mv 10.1155/2023/6407588
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9886468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A735993372</galeid><sourcerecordid>A735993372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-4ea760b80ce6ed7d4fe40975eddfdd95efa3628780dbd4569e9d02601ad35a733</originalsourceid><addsrcrecordid>eNp9kc2P0zAQxSMEYldlb5yRJS5IENaJHTvmsFKJyodUAYLlbE3jSZMlsYudUPa_x9mWCjjgy1ian968mZckjzP6MsuK4jKnObsUnMqiLO8l5znLeCoynt0__Rk7Sy5CuKHxlZmgSjxMzpiQuSiZOk_21y2SVdNgPRLXkKob_RQITB7s2E0DcZZ8cDb9MkDfpxX2PVlPdksqsDX6V2RJPmNA8HVLXkNAc8fjuHf-GwFryOrnDn03oB2hJ59a8APUrnfb20fJgwb6gBfHuki-vlldV-_S9ce376vlOq25FGPKEaSgm5LWKNBIwxvkVMkCjWmMUQU2wEReypKajeGFUKgMzQXNwLACJGOL5Oqgu5s2A5o6OvHQ6100Bf5WO-j03x3btXrrfmhVloLHGy2SZ0cB775PGEY9dKGOhwCLbgo6lzJTnDLBI_r0H_TGTd7G9WZqdinuHB2pLfSoO9u4OLeeRfVSskIpxmQeqRcHqvYuBI_NyXJG9Ry9nqPXx-gj_uTPNU_w76Aj8PwAtJ01sO_-L_cLDO21UQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2772878673</pqid></control><display><type>article</type><title>The Effect of Citrus aurantium on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology</title><source>Publicly Available Content (ProQuest)</source><source>Wiley Open Access</source><creator>Yao, Liangliang ; Zhang, Xuan ; Huang, Chaoming ; Cai, Yi ; Wan, Chunpeng (Craig)</creator><contributor>Yadav, Ajar Nath ; Ajar Nath Yadav</contributor><creatorcontrib>Yao, Liangliang ; Zhang, Xuan ; Huang, Chaoming ; Cai, Yi ; Wan, Chunpeng (Craig) ; Yadav, Ajar Nath ; Ajar Nath Yadav</creatorcontrib><description>Purpose. To screen the main active components of Citrus aurantium through a network pharmacology approach, construct a component-disease target network, explore its molecular mechanism for the treatment of non-small-cell lung cancer (NSCLC), and validate it experimentally. Methods. The active ingredients in Citrus aurantium and the targets of Citrus aurantium and NSCLC were collected through the Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform (TCMSP), GeneCards, and OMIM databases. The protein interaction network was constructed using the STRING database, and the component-disease relationship network graph was analyzed using Cytoscape 3.9.1. The Metascape database can be used for GO and KEGG enrichment analyses. The Kaplan-Meier plotter was applied for overall survival analysis of key targets of Citrus aurantium in the treatment of NSCLC. Real-time PCR (RT-PCR) and Western blotting were used to determine the mRNA and protein levels of key targets of Citrus aurantium for the treatment of NSCLC. Results. Five active ingredients of Citrus aurantium were screened, and 54 potential targets for the treatment of NSCLC were found, of which the key ingredient was nobiletin and the key targets are TP53, CXCL8, ESR1, PPAR-α, and MMP9. GO and KEGG enrichment analyses indicated that the mechanism of nobiletin in treating NSCLC may be related to the regulation of cancer signaling pathway, phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) signaling pathway, lipid and atherosclerosis signaling pathway, and neurodegenerative signaling pathway. The experimental results showed that nobiletin could inhibit the proliferation of NSCLC cells and upregulate the levels of P53 and PPAR-α and suppress the expression of MMP9 (P&lt;0.05). Conclusion. Citrus aurantium can participate in the treatment of NSCLC through multiple targets and pathways.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2023/6407588</identifier><identifier>PMID: 36726839</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>1-Phosphatidylinositol 3-kinase ; AKT protein ; Antibodies ; Arteriosclerosis ; Atherosclerosis ; Bioavailability ; Bitter orange ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Care and treatment ; Cell cycle ; Cell proliferation ; Chemical properties ; Chinese medicine ; Citrus ; Citrus aurantium ; Computer programs ; Drugs, Chinese Herbal - pharmacology ; ESR1 protein ; Fruits ; Gelatinase B ; Genes ; Health aspects ; Herbal medicine ; Identification and classification ; Ingredients ; Kinases ; Lipids ; Lung cancer ; Lung cancer, Non-small cell ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Matrix Metalloproteinase 9 ; Medical prognosis ; Medicine, Chinese Traditional ; Molecular Docking Simulation ; mRNA ; Non-small cell lung carcinoma ; p53 Protein ; Peroxisome Proliferator-Activated Receptors ; Pharmacology ; Physiological aspects ; Phytochemicals ; Proteins ; Signal transduction ; Signaling ; Software ; Statistical analysis ; Traditional Chinese medicine ; Variance analysis ; Western blotting</subject><ispartof>BioMed research international, 2023, Vol.2023 (1), p.6407588-6407588</ispartof><rights>Copyright © 2023 Liangliang Yao et al.</rights><rights>COPYRIGHT 2023 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2023 Liangliang Yao et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2023 Liangliang Yao et al. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-4ea760b80ce6ed7d4fe40975eddfdd95efa3628780dbd4569e9d02601ad35a733</citedby><cites>FETCH-LOGICAL-c476t-4ea760b80ce6ed7d4fe40975eddfdd95efa3628780dbd4569e9d02601ad35a733</cites><orcidid>0000-0001-6892-016X ; 0000-0003-2296-222X ; 0000-0002-8435-5954</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2772878673/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2772878673?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,4024,25753,27923,27924,27925,37012,37013,44590,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36726839$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Yadav, Ajar Nath</contributor><contributor>Ajar Nath Yadav</contributor><creatorcontrib>Yao, Liangliang</creatorcontrib><creatorcontrib>Zhang, Xuan</creatorcontrib><creatorcontrib>Huang, Chaoming</creatorcontrib><creatorcontrib>Cai, Yi</creatorcontrib><creatorcontrib>Wan, Chunpeng (Craig)</creatorcontrib><title>The Effect of Citrus aurantium on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>Purpose. To screen the main active components of Citrus aurantium through a network pharmacology approach, construct a component-disease target network, explore its molecular mechanism for the treatment of non-small-cell lung cancer (NSCLC), and validate it experimentally. Methods. The active ingredients in Citrus aurantium and the targets of Citrus aurantium and NSCLC were collected through the Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform (TCMSP), GeneCards, and OMIM databases. The protein interaction network was constructed using the STRING database, and the component-disease relationship network graph was analyzed using Cytoscape 3.9.1. The Metascape database can be used for GO and KEGG enrichment analyses. The Kaplan-Meier plotter was applied for overall survival analysis of key targets of Citrus aurantium in the treatment of NSCLC. Real-time PCR (RT-PCR) and Western blotting were used to determine the mRNA and protein levels of key targets of Citrus aurantium for the treatment of NSCLC. Results. Five active ingredients of Citrus aurantium were screened, and 54 potential targets for the treatment of NSCLC were found, of which the key ingredient was nobiletin and the key targets are TP53, CXCL8, ESR1, PPAR-α, and MMP9. GO and KEGG enrichment analyses indicated that the mechanism of nobiletin in treating NSCLC may be related to the regulation of cancer signaling pathway, phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) signaling pathway, lipid and atherosclerosis signaling pathway, and neurodegenerative signaling pathway. The experimental results showed that nobiletin could inhibit the proliferation of NSCLC cells and upregulate the levels of P53 and PPAR-α and suppress the expression of MMP9 (P&lt;0.05). Conclusion. Citrus aurantium can participate in the treatment of NSCLC through multiple targets and pathways.</description><subject>1-Phosphatidylinositol 3-kinase</subject><subject>AKT protein</subject><subject>Antibodies</subject><subject>Arteriosclerosis</subject><subject>Atherosclerosis</subject><subject>Bioavailability</subject><subject>Bitter orange</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Care and treatment</subject><subject>Cell cycle</subject><subject>Cell proliferation</subject><subject>Chemical properties</subject><subject>Chinese medicine</subject><subject>Citrus</subject><subject>Citrus aurantium</subject><subject>Computer programs</subject><subject>Drugs, Chinese Herbal - pharmacology</subject><subject>ESR1 protein</subject><subject>Fruits</subject><subject>Gelatinase B</subject><subject>Genes</subject><subject>Health aspects</subject><subject>Herbal medicine</subject><subject>Identification and classification</subject><subject>Ingredients</subject><subject>Kinases</subject><subject>Lipids</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Matrix Metalloproteinase 9</subject><subject>Medical prognosis</subject><subject>Medicine, Chinese Traditional</subject><subject>Molecular Docking Simulation</subject><subject>mRNA</subject><subject>Non-small cell lung carcinoma</subject><subject>p53 Protein</subject><subject>Peroxisome Proliferator-Activated Receptors</subject><subject>Pharmacology</subject><subject>Physiological aspects</subject><subject>Phytochemicals</subject><subject>Proteins</subject><subject>Signal transduction</subject><subject>Signaling</subject><subject>Software</subject><subject>Statistical analysis</subject><subject>Traditional Chinese medicine</subject><subject>Variance analysis</subject><subject>Western blotting</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kc2P0zAQxSMEYldlb5yRJS5IENaJHTvmsFKJyodUAYLlbE3jSZMlsYudUPa_x9mWCjjgy1ian968mZckjzP6MsuK4jKnObsUnMqiLO8l5znLeCoynt0__Rk7Sy5CuKHxlZmgSjxMzpiQuSiZOk_21y2SVdNgPRLXkKob_RQITB7s2E0DcZZ8cDb9MkDfpxX2PVlPdksqsDX6V2RJPmNA8HVLXkNAc8fjuHf-GwFryOrnDn03oB2hJ59a8APUrnfb20fJgwb6gBfHuki-vlldV-_S9ce376vlOq25FGPKEaSgm5LWKNBIwxvkVMkCjWmMUQU2wEReypKajeGFUKgMzQXNwLACJGOL5Oqgu5s2A5o6OvHQ6100Bf5WO-j03x3btXrrfmhVloLHGy2SZ0cB775PGEY9dKGOhwCLbgo6lzJTnDLBI_r0H_TGTd7G9WZqdinuHB2pLfSoO9u4OLeeRfVSskIpxmQeqRcHqvYuBI_NyXJG9Ry9nqPXx-gj_uTPNU_w76Aj8PwAtJ01sO_-L_cLDO21UQ</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Yao, Liangliang</creator><creator>Zhang, Xuan</creator><creator>Huang, Chaoming</creator><creator>Cai, Yi</creator><creator>Wan, Chunpeng (Craig)</creator><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6892-016X</orcidid><orcidid>https://orcid.org/0000-0003-2296-222X</orcidid><orcidid>https://orcid.org/0000-0002-8435-5954</orcidid></search><sort><creationdate>2023</creationdate><title>The Effect of Citrus aurantium on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology</title><author>Yao, Liangliang ; Zhang, Xuan ; Huang, Chaoming ; Cai, Yi ; Wan, Chunpeng (Craig)</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-4ea760b80ce6ed7d4fe40975eddfdd95efa3628780dbd4569e9d02601ad35a733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>1-Phosphatidylinositol 3-kinase</topic><topic>AKT protein</topic><topic>Antibodies</topic><topic>Arteriosclerosis</topic><topic>Atherosclerosis</topic><topic>Bioavailability</topic><topic>Bitter orange</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Care and treatment</topic><topic>Cell cycle</topic><topic>Cell proliferation</topic><topic>Chemical properties</topic><topic>Chinese medicine</topic><topic>Citrus</topic><topic>Citrus aurantium</topic><topic>Computer programs</topic><topic>Drugs, Chinese Herbal - pharmacology</topic><topic>ESR1 protein</topic><topic>Fruits</topic><topic>Gelatinase B</topic><topic>Genes</topic><topic>Health aspects</topic><topic>Herbal medicine</topic><topic>Identification and classification</topic><topic>Ingredients</topic><topic>Kinases</topic><topic>Lipids</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Matrix Metalloproteinase 9</topic><topic>Medical prognosis</topic><topic>Medicine, Chinese Traditional</topic><topic>Molecular Docking Simulation</topic><topic>mRNA</topic><topic>Non-small cell lung carcinoma</topic><topic>p53 Protein</topic><topic>Peroxisome Proliferator-Activated Receptors</topic><topic>Pharmacology</topic><topic>Physiological aspects</topic><topic>Phytochemicals</topic><topic>Proteins</topic><topic>Signal transduction</topic><topic>Signaling</topic><topic>Software</topic><topic>Statistical analysis</topic><topic>Traditional Chinese medicine</topic><topic>Variance analysis</topic><topic>Western blotting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yao, Liangliang</creatorcontrib><creatorcontrib>Zhang, Xuan</creatorcontrib><creatorcontrib>Huang, Chaoming</creatorcontrib><creatorcontrib>Cai, Yi</creatorcontrib><creatorcontrib>Wan, Chunpeng (Craig)</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Proquest Health &amp; Medical Complete</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Database‎ (1962 - current)</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Middle East &amp; Africa Database</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yao, Liangliang</au><au>Zhang, Xuan</au><au>Huang, Chaoming</au><au>Cai, Yi</au><au>Wan, Chunpeng (Craig)</au><au>Yadav, Ajar Nath</au><au>Ajar Nath Yadav</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effect of Citrus aurantium on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2023</date><risdate>2023</risdate><volume>2023</volume><issue>1</issue><spage>6407588</spage><epage>6407588</epage><pages>6407588-6407588</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Purpose. To screen the main active components of Citrus aurantium through a network pharmacology approach, construct a component-disease target network, explore its molecular mechanism for the treatment of non-small-cell lung cancer (NSCLC), and validate it experimentally. Methods. The active ingredients in Citrus aurantium and the targets of Citrus aurantium and NSCLC were collected through the Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform (TCMSP), GeneCards, and OMIM databases. The protein interaction network was constructed using the STRING database, and the component-disease relationship network graph was analyzed using Cytoscape 3.9.1. The Metascape database can be used for GO and KEGG enrichment analyses. The Kaplan-Meier plotter was applied for overall survival analysis of key targets of Citrus aurantium in the treatment of NSCLC. Real-time PCR (RT-PCR) and Western blotting were used to determine the mRNA and protein levels of key targets of Citrus aurantium for the treatment of NSCLC. Results. Five active ingredients of Citrus aurantium were screened, and 54 potential targets for the treatment of NSCLC were found, of which the key ingredient was nobiletin and the key targets are TP53, CXCL8, ESR1, PPAR-α, and MMP9. GO and KEGG enrichment analyses indicated that the mechanism of nobiletin in treating NSCLC may be related to the regulation of cancer signaling pathway, phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) signaling pathway, lipid and atherosclerosis signaling pathway, and neurodegenerative signaling pathway. The experimental results showed that nobiletin could inhibit the proliferation of NSCLC cells and upregulate the levels of P53 and PPAR-α and suppress the expression of MMP9 (P&lt;0.05). Conclusion. Citrus aurantium can participate in the treatment of NSCLC through multiple targets and pathways.</abstract><cop>United States</cop><pub>Hindawi</pub><pmid>36726839</pmid><doi>10.1155/2023/6407588</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-6892-016X</orcidid><orcidid>https://orcid.org/0000-0003-2296-222X</orcidid><orcidid>https://orcid.org/0000-0002-8435-5954</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2314-6133
ispartof BioMed research international, 2023, Vol.2023 (1), p.6407588-6407588
issn 2314-6133
2314-6141
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9886468
source Publicly Available Content (ProQuest); Wiley Open Access
subjects 1-Phosphatidylinositol 3-kinase
AKT protein
Antibodies
Arteriosclerosis
Atherosclerosis
Bioavailability
Bitter orange
Cancer therapies
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Care and treatment
Cell cycle
Cell proliferation
Chemical properties
Chinese medicine
Citrus
Citrus aurantium
Computer programs
Drugs, Chinese Herbal - pharmacology
ESR1 protein
Fruits
Gelatinase B
Genes
Health aspects
Herbal medicine
Identification and classification
Ingredients
Kinases
Lipids
Lung cancer
Lung cancer, Non-small cell
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Matrix Metalloproteinase 9
Medical prognosis
Medicine, Chinese Traditional
Molecular Docking Simulation
mRNA
Non-small cell lung carcinoma
p53 Protein
Peroxisome Proliferator-Activated Receptors
Pharmacology
Physiological aspects
Phytochemicals
Proteins
Signal transduction
Signaling
Software
Statistical analysis
Traditional Chinese medicine
Variance analysis
Western blotting
title The Effect of Citrus aurantium on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A59%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effect%20of%20Citrus%20aurantium%20on%20Non-Small-Cell%20Lung%20Cancer:%20A%20Research%20Based%20on%20Network%20and%20Experimental%20Pharmacology&rft.jtitle=BioMed%20research%20international&rft.au=Yao,%20Liangliang&rft.date=2023&rft.volume=2023&rft.issue=1&rft.spage=6407588&rft.epage=6407588&rft.pages=6407588-6407588&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2023/6407588&rft_dat=%3Cgale_pubme%3EA735993372%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c476t-4ea760b80ce6ed7d4fe40975eddfdd95efa3628780dbd4569e9d02601ad35a733%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2772878673&rft_id=info:pmid/36726839&rft_galeid=A735993372&rfr_iscdi=true